Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference
25 Febbraio 2025 - 2:00PM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunologic diseases, today announced that Jill C. Milne,
Ph.D., Chief Executive Officer, will participate in a fireside chat
at the upcoming TD Cowen 45th Annual Health Care Conference on
Tuesday, March 4th at 9:50am ET in Boston, MA.
A webcast of the presentation can be accessed at the following
link: https://wsw.com/webcast/cowen177/atxs/2050656. An archived
replay of the presentation will be available in the investors
section of www.astriatx.com for 30 days following the event.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunologic diseases. Our lead
program, navenibart (STAR-0215), is a monoclonal antibody inhibitor
of plasma kallikrein in clinical development for the treatment of
hereditary angioedema. Our second program, STAR-0310, is a
monoclonal antibody OX40 antagonist in clinical development for the
treatment of atopic dermatitis. Learn more about our company on our
website, www.astriatx.com, or follow us on Instagram @AstriaTx and
on Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250225377705/en/
Astria: Investor Relations and
Media: Elizabeth Higgins investors@astriatx.com
Grafico Azioni Astria Therapeutics (NASDAQ:ATXS)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Astria Therapeutics (NASDAQ:ATXS)
Storico
Da Mar 2024 a Mar 2025
